On August 1, 2026, world-leading medical laser and energy-based device company Fotona announced the creation of the Chief Product Officer (CPO) role, naming MedTech veteran Alasdair Owen to the position effective August 24, 2026.
Owen will report directly to President and CEO Jeff Duchemin and lead the company’s global product and innovation strategy, including oversight of Research & Development, product portfolio strategy, and innovation initiatives worldwide.
Related: StarFormer Magnetic Stimulation Improves Abdominal Contours
Owen's oversight of R&D and portfolio strategy comes as the laser company looks to invest in its product pipeline and accelerate innovation rooted in evolving practitioner and patient needs.
Owen will be tasked with strengthening the company's strategy and R&D capabilities, translating portfolio insights into technologies that improve outcomes, experiences, business success, and advance solutions across aesthetics, dermatology, dentistry, women's health, and surgery.
Working across the organization and in close collaboration with practitioners, he will identify emerging clinical needs and guide the advancement of future product platforms that support practitioners, enhance performance, and improve patient outcomes globally.
“Alasdair has a unique ability to connect practitioner and patient insights, technology, and business strategy that will help us move faster to deliver new solutions that our customers need,” said Jeff Duchemin, President and CEO of Fotona. "As we continue to expand across specialties and geographies, his leadership will strengthen our ability to deliver solutions that improve clinical outcomes, elevate patient experiences, and help practitioners grow their practices."
Fotona's new Chief Product Officer role reflects the company’s growing focus on expanding treatment categories and accelerating the journey from customer insight to commercialized solutions.
For practices investing in energy-based platforms, Fotona's investment in translating practitioner needs into new technologies, treatment categories, and commercial opportunities could mean new modalities, expanded indications, and tools designed for practice growth.
